Autoimmune hepatitis: Mycophenolate mofetil vs. azathioprine as first-line therapy

J Hepatol. 2024 Jul;81(1):e41-e42. doi: 10.1016/j.jhep.2024.02.022. Epub 2024 Mar 6.

Authors

Cem Şimşek¹, Staffan Wahlin², Cumali Efe³

Affiliations

¹ Department of Gastroenterology, Hacettepe University, Ankara, Turkey.
² Hepatology Division, Department of Upper GI Diseases, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
³ Department of Gastroenterology, Harran University, Şanlıurfa, Turkey. Electronic address: scumaliefe@gmail.com.

PMID: 38458322
DOI: 10.1016/j.jhep.2024.02.022

No abstract available

Publication types

Comparative Study
Letter

MeSH terms

Azathioprine* / administration & dosage
Azathioprine* / adverse effects
Azathioprine* / therapeutic use
Hepatitis, Autoimmune* / drug therapy
Humans
Immunosuppressive Agents* / adverse effects
Immunosuppressive Agents* / therapeutic use
Mycophenolic Acid* / adverse effects
Mycophenolic Acid* / therapeutic use

Substances

Mycophenolic Acid
Azathioprine
Immunosuppressive Agents